Product Description

From the editor of the most influential biotech newsletter comes the most comprehensive investment guide on biotechnology.

Biotechnology is indisputably one of the fastest-growing and most promising industries. Virtually immune to swings in the economic cycles, biotech stocks continue to perform steadily as high-tech stocks lose their steam.

In Biotech Investing, Jim McCamant offers proven strategies and savvy advice on how to capitalize on the unprecedented opportunities in this high-potential sector. Written by a recognized authority, this book dissects biotech business models from start-up to IPO and discusses in detail the most important factors that affect biotech research. Comprehensive in scope, it looks at the best and worst biotech contenders, discusses all the most newsworthy developments in the field, and shows how they translate into business success or failure. It outlines simple criteria for choosing the best biotech stocks and for understanding the sometimes complicated dynamics of this sector.

Product Details

• Amazon Sales Rank: #1002410 in Books
• Published on: 2002-06-15
• Released on: 2002-06-04
• Original language: English
• Number of items: 1
• Binding: Hardcover
• 224 pages

From Library Journal
Editor of the Medical Technology Stock Letter since the mid-1980s, McCamant uses his experience to provide a broad and deep overview of this exciting juncture of science and commerce. He focuses on why he thinks, from an investor's perspective, that now is such a propitious time to get into the market. Chapters cover a history of the field, how to invest, a state-of-the-art summary of biotechnology, patents and the clinical review process, and the future of biotechnology. Pharmaceutical companies, as opposed to strictly research companies, are particularly well situated to benefit from biotech advances, as they have both the research infrastructure and the capital to last through the long and expensive process of clinical studies. McCamant also includes a chapter on his investment philosophy that is succinct, logical, and itself worth the price of the book. Strongly recommended for academic and public libraries serving an investment public. Patrick J. Brunet, Western Wisconsin Technical Coll. Lib., LaCrosse
Copyright 2002 Cahners Business Information, Inc.

About the Author
Jim McCamant is editor of the Medical Technology Stock Letter, the oldest biotech newsletter in the country. A nationally recognized authority in biotech investing, he is a constant news source for major media publications, including BusinessWeek, the Wall Street Journal, and Worth Magazine. He lives in Berkeley, California.

Customer Reviews

Guide, but not an *Investors* guide
I picked up this book with two kinds of expectations. One that McCamant would give me the "lay of the land" of the Biotech space, the competing markets and the key companies. The other, that he would provide deep insight (a la Peter Lynch) on an investment method. On the first count, the book does a reasonable job. On the second count, it is very disappointing. Most of the investment rules are obvious and generic. The investment web links are outdated.

Science good, investment insight bad
Disappointing. I guess this book is one example where the cover says it all; next time I see a book on Biotech investing, I want to see a dollar sign on the jacket.
Sure, I got the biotech bit, but where was the insight into investing. Nothing really hit me. I started reading the book not knowing how to invest in biotech; I ended the same way.

On a positive note, I did like the writing style.

Excellent Advice!
WOW! Such a dense topic, so carefully written. I am the wiser for this book. Thank you for presenting this so clearly.